Pharmacogenomics toward personalized tamoxifen therapy for breast cancer

Pharmacogenomics

Volumn 16, Issue 3, 2015, Pages 287-296

  Zembutsu, Hitoshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

ABCC2; C10orf11; CYP2D6; dose adjustment; endoxifen; pharmacogenomics; tamoxifen

Indexed keywords

AFIMOXIFENE; AMFEBUTAMONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; DRUG METABOLITE; DULOXETINE; ENDOXIFEN; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GENETIC MARKER;

BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENETIC VARIABILITY; GENOTYPE; HOT FLUSH; HUMAN; NULL ALLELE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; REVIEW; BREAST NEOPLASMS; DRUG INTERACTION; FEMALE; GENETIC MARKER; GENETICS; METABOLISM; TRENDS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; DRUG INTERACTIONS; FEMALE; GENETIC MARKERS; GENETIC VARIATION; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PRECISION MEDICINE; TAMOXIFEN;

EID: 84923650448     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.171     Document Type: Review

References (86)

1. Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793), 771-784 (2011
2. Davies C, Pan H, Godwin J et al. Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869), 805-816 (2013
3. Borgna Jl, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256(2), 859-868 (1981
4. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49(8), 2175-2183 (1989
5. Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85(2), 151-159 (2004
6. CYP2D6 allele nomenclature. www.cypalleles.ki.se/cyp2d6.htm
7. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284-295 (1997
8. Griese Eu, Zanger UM, Brudermanns U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8(1), 15-26 (1998
9. Irvin WJ Jr, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24), 3232-3239 (2011
10. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 10(8), 545-558 (1991
11. Madlensky L, Natarajan L, Tchu S et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89(5), 718-725 (2011
12. Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6&z.ast;10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99(5), 995-999 (2008
13. Hosono N, Kato M, Kiyotani K et al. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin. Chem. 55(8), 1546-1554 (2009
14. Kiyotani K, Mushiroda T, Imamura CK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28(8), 1287-1293 (2010
15. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007
16. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009
17. Province MA, Goetz MP, Brauch H et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin. Pharmacol. Ther. 95(2), 216-227 (2014
18. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25(25), 3837-3845 (2007
19. Kiyotani K, Mushiroda T, Imamura CK et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res. Treat. 131(1), 137-145 (2012
20. Martinez De Duenas E, Ochoa Aranda E, Blancas Lopez- Barajas I et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype. Breast 23(4), 400-406 (2014
21. Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J. Natl Cancer Inst. 104(6), 441-451 (2012
22. Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91(3), 249-258 (2005
23. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9(1), R7 (2007
24. Hertz Dl, Mcleod Hl, Irvin WJ Jr. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 17(5), 620-630 (2012
25. Ingle JN, Suman VJ, Johnson PA et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res. 5(7), 1642-1649 (1999
26. Stearns V, Johnson Md, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23), 1758-1764 (2003
27. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005
28. Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22(47), 7316-7339 (2003
29. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 48(8), 2304-2308 (1988
30. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062-1075 (2004
31. Gjerde J, Hauglid M, Breilid H et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19(1), 56-61 (2008
32. Falany JL, Pilloff DE, Leyh TS, Falany CN. Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab. Dispos. 34(3), 361-368 (2006
33. Nishiyama T, Ogura K, Nakano H et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem. Pharmacol. 63(10), 1817-1830 (2002
34. Ogura K, Ishikawa Y, Kaku T et al. Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem. Pharmacol. 71(9), 1358-1369 (2006
35. Sun D, Sharma AK, Dellinger RW et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab. Dispos. 35(11), 2006-2014 (2007
36. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6-13 (2005
37. Gross AS, Kroemer Hk, Eichelbaum M. Genetic polymorphism of drug metabolism in humans. Adv. Exp. Med. Biol. 283, 627-640 (1991
38. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17(2), 93-101 (2007
39. Sideras K, Ingle JN, Ames MM et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol. 28(16), 2768-2776 (2010
40. Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80(1), 61-74 (2006
41. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247), 2059-2063 (2000
42. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 20(6), 1578-1583 (2002
43. Stearns V, Beebe Kl, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289(21), 2827-2834 (2003
44. Orleans RJ, Li L, Kim MJ et al. FDA approval of paroxetine for menopausal hot flushes. N. Engl. J. Med. 370(19), 1777-1779 (2014
45. Zembutsu H, Sasa M, Kiyotani K, Mushiroda T, Nakamura Y. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?. Expert Rev. Anticancer Ther. 11(2), 185-193 (2011
46. Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev. 18(9), 2562-2564 (2009
47. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010(8), 340 (2010
48. Siegelmann-Danieli N, Kurnik D, Lomnicky Y et al. Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res. Treat. 125(2), 505-510 (2011
49. Desmarais JE, Looper KJ. Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas 67(4), 296-308 (2010
50. Dezentje VO, Van Blijderveen NJ, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol. 28(14), 2423-2429 (2010
51. Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res. Treat. 137(1), 285-296 (2013
52. Higgins Mj, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr. Oncol. Rep. 12(1), 7-15 (2010
53. Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3), R284-R290 (2005
54. Xu Y, Sun Y, Yao L et al. Association between CYP2D6 &z.ast;10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19(8), 1423-1429 (2008
55. Ramon Y, Cajal T, Altes A, Pare L et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat. 119(1), 33-38 (2010
56. Abraham JE, Maranian MJ, Driver KE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 12(4), R64 (2010
57. Goetz MP, Suman VJ, Hoskin TL et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin. Cancer Res. 19(2), 500-507 (2013
58. Newman WG, Hadfield KD, Latif A et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res. 14(18), 5913-5918 (2008
59. Teh LK, Mohamed NI, Salleh MZ et al. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J. 14(1), 52-59 (2012
60. Sirachainan E, Jaruhathai S, Trachu N et al. CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmgenomics Pers. Med. 5, 149-153 (2012
61. Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother. Pharmacol. 70(1), 75-81 (2012
62. Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115(5), 952-961 (2009
63. Stingl JC, Parmar S, Huber-Wechselberger A et al. Impact of CYP2D6&z.ast;4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr. Med. Res. Opin. 26(11), 2535-2542 (2010
64. Kiyotani K, Mushiroda T, Hosono N et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics 20(9), 565-568 (2010
65. Lash TL, Cronin-Fenton D, Ahern TP et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J. Natl Cancer Inst. 103(6), 489-500 (2011
66. Park Ih, Ro J, Park S et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res. Treat. 131(2), 455-461 (2012
67. Park HS, Choi JY, Lee MJ et al. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J. Korean Med. Sci. 26(8), 1007-1013 (2011
68. Thompson AM, Johnson A, Quinlan P et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125(1), 279-287 (2011
69. Rae JM, Drury S, Hayes DF et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-Treated breast cancer patients. J. Natl Cancer Inst. 104(6), 452-460 (2012
70. Kiyotani K, Mushiroda T, Zembutsu H, Nakamura Y. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J. Hum. Genet. 58(6), 327-333 (2013
71. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J. Natl Cancer Inst. 104(16), 1264; author reply 1266-1268 (2012
72. Hoskins JM, Carey LA, Mcleod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586. (2009
73. Lash TL, Rosenberg CL. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J. Clin. Oncol. 28(8), 1273-1275 (2010
74. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312-9318 (2005
75. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33), 5187-5193 (2007
76. Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 217(1), 61-72 (2005
77. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19&z.ast;17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83(2), 322-327 (2008
78. Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103-113 (2006
79. Kiyotani K, Mushiroda T, Tsunoda T et al. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum. Mol. Genet. 21(7), 1665-1672 (2012
80. Grabinski JL, Smith LS, Chisholm GB et al. Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Res. Treat. 95(1), 13-16 (2006
81. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001
82. Murdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89(5), 708-717 (2011
83. Gjerde J, Geisler J, Lundgren S et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10, 313 (2010
84. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 54(10), 1311-1331 (2002
85. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokinet. 17(1), 23-33 (2002
86. Kisanga ER, Mellgren G, Lien EA. Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Res. 25(6C), 4487-4492 (2005